Cover Image
市場調查報告書

PharmaPoint:胃、胃食道結點腺癌 - 全球醫藥品市場預測與市場分析

PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 354678
出版日期 內容資訊 英文 409 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:胃、胃食道結點腺癌 - 全球醫藥品市場預測與市場分析 PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024
出版日期: 2015年12月09日 內容資訊: 英文 409 Pages
簡介

胃、胃食道結點腺癌治療藥市場2014年的銷售額,在主要8個國家是11億3千萬美元。2024年預計達到43億9千萬美元,以14.6%的年複合成長率成長。

本報告提供胃、胃食道結點腺癌市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分期
  • 症狀
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測:胃癌
    • 確診的發病數量
    • 確診的發病數量:各年齡
    • 確診的發病數量:性別
    • 確診的發病數量:年齡調整等
  • 討論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第6章 競爭評估

  • 概要
  • HER2標靶治療
  • 血管新生抑制劑
  • 化療

第7章 未滿足需求和機會

第8章 開發平台評估

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Merck & Co.
    • Roche
    • 大鵬藥品工業
    • 大日本住友製藥

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本
  • 中國

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC123PIDR

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

GlobalData estimates the 2014 sales for G/GEJAC at approximately $1.13 billion across the 8MM covered in this report. The market is expected to reach $4.39 billion in 2024 at a CAGR of 14.6%. This growth will be mainly driven by the approval and uptake of premium-priced products, such as Eli Lilly's Cyramza (ramucirumab) and PD-1-targeting mAbs, Merck & Co.'s Keytruda (pembrolizumab) and BMS' Opdivo (nivolumab). GlobalData expects, by the end of the forecast period, Cyramza to dominate the G/GEJAC market with an overall 37% share of the G/GEJAC market.

The G/GEJAC pipeline is strong; however, GlobalData expects many of these drugs to launch only in Japan and China, limiting their outlook. For the pipeline drugs that are in a global development. Roche's Perjeta (pertuzumab) and Merck & Co.'s Keytruda are the most promising. While the HER2-positive segment of the G/GEJAC will be dominated by Roche over the forecast period, GlobalData projects there will be opportunities for companies to develop novel therapeutics targeting the HER2-negative first-line setting.

Highlights

Key Questions Answered

  • What will be the impact of the new anti-PD-1 inhibitors and their projected label expansions on the G/GEJAC market sales? Given the recent reports on clinical efficacy of these pipeline drugs, there is a good deal of potential in the G/GEJAC space for anti-PD-1 inhibitors over the forecast period.
  • As the HER2-positive segment of the G/GEJAC market is dominated by Roche, pharmaceutical companies aim to establish their foothold in the underserved HER2-negative space. What R&D strategies are being pursued by drug makers to stand out?
  • The development of drugs for G/GEJAC has been slow, especially after the failure of Phase III trials of multiple pre-2014 pipeline agents. Therefore, there are considerable high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the G/GEJAC market?

Key Findings

  • One of the main drivers of the enormous expansion of the G/GEJAC market will be the launch of premium-priced metastatic therapies, such as HER2-targeted therapy Perjeta, and anti-PD-1 immunotherapies Keytruda and Opdivo. The uptake of recently-approved Cyramza and its projected label expansion into the HER2-negative first-line setting will also be key. These drugs will extend treatment duration and will be added onto the current standard-of-care regimens.
  • Key patent expiry of Herceptin across the major markets and subsequent biosimilar entries expected starting in 2017 represent a major barrier of the growth of the G/GEJAC market. GlobalData expects trastuzumab biosimilars to occupy a fifth of total molecule sales in 2024, the end of the forecast period.
  • Companies are focusing on the development of therapies for the second-line treatment and for HER2-negative patients in the first line, trying to avoid excessive competition with the current standard of care.
  • One of the largest unmet needs is efficacious perioperative and postoperative treatment options for resected patients to prevent disease recurrence. Currently, no company-sponsored trials are planed to address this unmet need.

Scope

  • Overview of G/GEJAC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized G/GEJAC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments (including adjuvant, HER2-positive and HER2-negative), forecast from 2014 to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the G/GEJAC therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global G/GEJAC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global G/GEJAC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Biomarkers/Targets of Interest
  • 3.2. Staging
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. 8MM, Incidence Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Cancer - 8MM
    • 4.4.4. Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Gastric Cancer - 8MM
    • 4.4.5. Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at Diagnosis - 8MM
    • 4.4.6. Forecast Assumptions and Methods, Gastric Cancer Cellular Types - 8MM
    • 4.4.7. Forecast Assumptions and Methods, HER2 Status - 8MM
    • 4.4.8. Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ Cancer - 8MM
    • 4.4.9. Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Adenocarcinomas - 8MM
  • 4.5. Epidemiological Forecast of Gastric Cancer (2014-2024)
    • 4.5.1. Diagnosed Incident Cases of Gastric Cancer
    • 4.5.2. Age-Specific Diagnosed Incident Cases of Gastric Cancer
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of Gastric Cancer
    • 4.5.4. Age-Standardized Diagnosed Incidence of Gastric Cancer
    • 4.5.5. Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis
    • 4.5.6. Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Cellular Type
    • 4.5.7. Diagnosed Incident Cases of Gastric Cancer by HER2 Status
    • 4.5.8. Diagnosed Incident Cases of GEJ Cancer
    • 4.5.9. Five-Year Diagnosed Prevalent Cases of Gastric Cancer
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Screening
    • 5.1.2. Diagnosis
    • 5.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.4. Clinical Practice
  • 5.2. US
    • 5.2.1. Screening and Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Screening and Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Screening and Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Screening and Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Screening and Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Screening and Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Screening and Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Screening and Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. HER2-Targeted Therapy
    • 6.2.1. Herceptin (trastuzumab)
  • 6.3. Angiogenesis Inhibitors
    • 6.3.1. Cyramza (ramucirumab)
    • 6.3.2. Aitan (apatinib)
  • 6.4. Chemotherapies
    • 6.4.1. TS-1 (tegafur, gimeracil, oteracil)
    • 6.4.2. Abraxane (nab-paclitaxel)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. First-Line Therapy for HER2-Negative Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. New Molecular Targets for Targeted Therapies
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Effective Perioperative and Postoperative Therapies
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. More Efficacious HER2-Targeted Therapies
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Peritoneal Metastases
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Better Clinical Trial Design
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity
  • 7.8. Early Detection of Gastric and Gastroesophageal Adenocarcinomas
    • 7.8.1. Unmet Need
    • 7.8.2. Gap Analysis
    • 7.8.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Phase III Clinical Development
  • 8.3. HER2-Targeted Therapies
    • 8.3.1. Kadcyla (T-DM1; trastuzumab emtansine)
    • 8.3.2. Perjeta (pertuzumab)
  • 8.4. Immune Checkpoint Inhibitors
    • 8.4.1. Keytruda (pembrolizumab)
    • 8.4.2. Opdivo (nivolumab)
  • 8.5. Further Strategies for G/GEJAC Treatment
    • 8.5.1. Napabucasin
    • 8.5.2. Lynparza (olaparib)
    • 8.5.3. Nimotuzumab
    • 8.5.4. TAS-118
  • 8.6. Early/Near-Phase III Pipeline Drugs
    • 8.6.1. GS-5745
    • 8.6.2. Masitinib
  • 8.7. Promising Drugs in Early-Stage Development
    • 8.7.1. Immune Checkpoint Inhibitors
    • 8.7.2. MET-Targeting Drugs
    • 8.7.3. Antibody-Drug Conjugates
  • 8.8. Biosimilars

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Bristol-Myers Squibb
    • 9.3.2. Eli Lilly and Company
    • 9.3.3. Merck & Co.
    • 9.3.4. Roche
    • 9.3.5. Taiho Pharmaceutical
    • 9.3.6. Sumitomo Dainippon Pharma

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers - US
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers - France
    • 10.3.4. Drivers and Barriers - Germany
    • 10.3.5. Drivers and Barriers - Italy
    • 10.3.6. Drivers and Barriers - Spain
    • 10.3.7. Drivers and Barriers - UK
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers - Japan
  • 10.5. China
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers - China

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed G/GEJAC Patients
    • 11.4.2. Percent of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - Key Opinion Leaders Interviewed for this Report
  • 11.6. Primary Research - High-Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Stage Definitions for Gastric Cancer
  • Table 2: Symptoms of Gastric Cancer
  • Table 3: Prognosis of Gastric Cancer in the US and UK
  • Table 4: Risk Factors and Comorbidities for Gastric Cancer
  • Table 5: 8MM, Sources of Gastric Cancer Incidence Data
  • Table 6: 8MM, Sources Used in the Epidemiology Forecast for the Five-Year Diagnosed Prevalent Cases of Gastric Cancer
  • Table 7: 8MM, Sources of Gastric Cancer Stage at Diagnosis According to AJCC, TNM (Tumor, Node, Metastasis) Staging Manual
  • Table 8: 8MM, Sources of Distribution of Gastric Cancer Cases at Diagnosis by Cellular Type
  • Table 9: 8MM, Sources of GEJ Cancer Incidence Data
  • Table 10: 8MM, Sources of HER2-Positive Status in Diagnosed Incident Cases of Gastric Cancer
  • Table 11: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Table 12: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N (Row %), 2014
  • Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ≥20 Years, N (Row %), 2014
  • Table 14: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ≥20 Years, N (Row %), 2014
  • Table 15: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Table 17: Clinical Guidelines for Gastric Cancer
  • Table 18: Generic Chemotherapy Regimens Indicated for Gastric Cancer
  • Table 19: Country Profile - US
  • Table 20: Country Profile - France
  • Table 21: Country Profile - Germany
  • Table 22: Country Profile - Italy
  • Table 23: Country Profile - Spain
  • Table 24: Country Profile - UK
  • Table 25: Country Profile - Japan
  • Table 26: Country Profile - China
  • Table 27: Leading Treatments for G/GEJAC, 2015
  • Table 28: Product Profile - Herceptin
  • Table 29: Summary of Results from the ToGA Trial of Herceptin plus FC
  • Table 30: Summary of the Results of the Analysis of the HER2 IHC3+ or IHC2+/FISH+ Subgroup
  • Table 31: Summary of AEs from the ToGA Trial of Herceptin plus FC
  • Table 32: Herceptin SWOT Analysis, 2015
  • Table 33: Global Sales Forecasts ($m) for Herceptin, 2014-2024
  • Table 34: Product Profile - Cyramza
  • Table 35: Summary of the Results from the REGARD of Cyramza
  • Table 36: Summary of the Results from the RAINBOW Trial of Cyramza plus Paclitaxel
  • Table 37: Summary of Trial Results of Cyramza in Combination with mFOLFOX6 in the First-Line Setting
  • Table 38: Summary of AEs from the REGARD Trial of Cyramza Monotherapy
  • Table 39: Summary of AEs from the RAINBOW Trial of Cyramza plus Paclitaxel
  • Table 40: Cyramza SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Cyramza, 2014-2024
  • Table 42: Product Profile - Aitan
  • Table 43: Summary of Aitan Trial Results
  • Table 44: Summary of AEs from Phase III Trial of Aitan
  • Table 45: Aitan SWOT Analysis, 2015
  • Table 46: Global Sales Forecasts ($m) for Aitan, 2014-2024
  • Table 47: Product Profile - TS-1
  • Table 48: Summary of the Results of Three Studies of TS-1 Monotherapy
  • Table 49: Summary of the Results from the ACTS-GC Study of TS-1
  • Table 50: Summary of TS-1 in the DIGEST trial
  • Table 51: Summary of AEs from ACTS=GS Trial of TS-1 Adjuvant Treatment
  • Table 52: Summary of AEs from Trial of TS-1 plus Cisplatin
  • Table 53: TS-1 SWOT Analysis, 2015
  • Table 54: Global Sales Forecasts ($m) for TS-1, 2014-2024
  • Table 55: Product Profile - Abraxane
  • Table 56: Summary of Results from a Phase II Trial of Abraxane
  • Table 57: Safety of Abraxane
  • Table 58: Abraxane SWOT Analysis, 2015
  • Table 59: Global Sales Forecasts ($m) for Abraxane, 2014-2024
  • Table 60: Unmet Needs and Opportunities in G/GEJAC
  • Table 61: Product Profile - Kadcyla
  • Table 62: Kadcyla SWOT Analysis, 2015
  • Table 63: Product Profile - Perjeta
  • Table 64: Summary of the Results of the Phase IIa Trial of the Herceptin/Perjeta-CX Combination
  • Table 65: Safety of the Herceptin/Perjeta-CX Combination
  • Table 66: Perjeta SWOT Analysis, 2015
  • Table 67: Global Sales Forecasts ($m) for Perjeta, 2014-2024
  • Table 68: Product Profile - Keytruda
  • Table 69: Summary of the Results of the KEYNOTE-012 Trial of Keytruda
  • Table 70: Keytruda SWOT Analysis, 2015
  • Table 71: Global Sales Forecasts ($m) for Keytruda, 2014-2024
  • Table 72: Product Profile - Opdivo
  • Table 73: Opdivo SWOT Analysis, 2015
  • Table 74: Global Sales Forecasts ($m) for Opdivo, 2014-2024
  • Table 75: Product Profile - Napabucasin
  • Table 76: Summary of the Results from the Phase Ib/II Trial of Napabucasin
  • Table 77: Napabucasin SWOT Analysis, 2015
  • Table 78: Global Sales Forecasts ($m) for Napabucasin, 2014-2024
  • Table 79: Product Profile - Lynparza
  • Table 80: Summary of Results of the Phase II Trial of Lynparza
  • Table 81: Summary of AEs from Phase II Trial of Lynparza
  • Table 82: Lynparza SWOT Analysis, 2015
  • Table 83: Global Sales Forecasts ($m) for Lynparza, 2014-2024
  • Table 84: Product Profile - Nimotuzumab
  • Table 85: Summary of the Results of the Phase II Trial of Nimotuzumab in Unselected Patients
  • Table 86: Summary of the Results of the Subgroup Analysis of Nimotuzumab in EGFR-Positive Patients
  • Table 87: Summary of AEs from the Phase II Trial of Nimotuzumab in Combination with Irinotecan
  • Table 88: Nimotuzumab SWOT Analysis, 2015
  • Table 89: Global Sales Forecasts ($m) for nimotuzumab, 2014-2024
  • Table 90: Product Profile - TAS-118
  • Table 91: TAS-118 SWOT Analysis, 2015
  • Table 92: Global Sales Forecasts ($m) for TAS-118, 2014-2024
  • Table 93: Product Profile - GS-5745
  • Table 94: GS-5745 SWOT Analysis
  • Table 95: Product Profile - Masitinib
  • Table 96: Summary of the Results of the Phase II Trial of the Masitinib-Chemotherapy Combinations
  • Table 97: Summary of AEs from the Phase II Trial of the Masitinib-Chemotherapy Combinations
  • Table 98: Masitinib SWOT Analysis, 2013
  • Table 99: Early-Stage Immune Checkpoint Inhibitors
  • Table 100: Early-Stage MET-Targeting Drugs
  • Table 101: Early-Stage Antibody-Drug-Conjugates
  • Table 102: Marketed or Phase III Trastuzumab Biosimilars
  • Table 103: Key Companies in the G/GEJAC Market in the 8MM, 2014-2024
  • Table 104: BMS' G/GEJAC Portfolio Assessment, 2015
  • Table 105: Eli Lilly's G/GEJAC Portfolio Assessment, 2015
  • Table 106: Merck & Co.'s G/GEJAC Portfolio Assessment, 2015
  • Table 107: Roche's G/GEJAC Portfolio Assessment, 2015
  • Table 108: Taiho's G/GEJAC Portfolio Assessment, 2015
  • Table 109: SDP's G/GEJAC Portfolio Assessment, 2015
  • Table 110: Global Sales Forecast ($m) for G/GEJAC, 2014-2024
  • Table 111: G/GEJAC Market - Drivers and Barriers, 2015
  • Table 112: Sales Forecast ($m) for G/GEJAC in the US, 2014-2024
  • Table 113: Key Events Impacting Sales for G/GEJAC in the US, 2014-2024
  • Table 114: G/GEJAC Market in the US - Drivers and Barriers, 2015
  • Table 115: Sales Forecast ($m) for G/GEJAC in the 5EU, 2014-2024
  • Table 116: Key Events Impacting Sales for G/GEJAC in the 5EU, 2014-2024
  • Table 117: G/GEJAC Market in France - Drivers and Barriers, 2015
  • Table 118: G/GEJAC Market in Germany - Drivers and Barriers, 2015
  • Table 119: G/GEJAC Market in Italy - Drivers and Barriers, 2015
  • Table 120: G/GEJAC Market in Spain - Drivers and Barriers, 2015
  • Table 121: G/GEJAC Market in the UK - Drivers and Barriers, 2015
  • Table 122: Sales Forecast ($m) for Gastric Cancer in Japan, 2014-2024
  • Table 123: Key Events Impacting Sales for Gastric Cancer in Japan, 2014-2024
  • Table 124: Gastric Cancer Market in Japan - Drivers and Barriers, 2015
  • Table 125: Sales Forecast ($m) for G/GEJAC in China, 2014-2024
  • Table 126: Key Events Impacting Sales for G/GEAJC in China, 2014-2024
  • Table 127: G/GEJAC Market in China - Drivers and Barriers, 2015
  • Table 128: Key Launch Dates
  • Table 129: Key Patent Expiries
  • Table 130 Average Body Weight and Surface Area Across the 8MM
  • Table 131: Average Cost of Therapy of Herceptin
  • Table 132: Average Cost of Therapy of Cyramza
  • Table 133: Average Cost of Therapy of TS-1
  • Table 134: Average Cost of Therapy of Abraxane
  • Table 135: High-Prescribing Physicians Surveyed by Country

List of Figures

  • Figure 1: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Men, 1998-2007
  • Figure 2: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Women, 1998-2007
  • Figure 3: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N, 2014
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ≥20 Years, 2014
  • Figure 6: 8MM, Age-Standardized Diagnosed Incidence of Gastric Cancer (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2014
  • Figure 7: 8MM, Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis, Both Sexes, Ages ≥20 Years
  • Figure 8: 8MM, Percentage Distribution of Diagnosed Incident Cases Gastric Cancer, by Cellular Type, Both Sexes, Ages ≥20 Years
  • Figure 9: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ≥20 Years, %, 2014
  • Figure 10: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 12: Treatment Flowchart for Localized Gastric Cancer
  • Figure 13: Treatment Flowchart for Locoregional Gastric cancer
  • Figure 14: Treatment Flowchart for Metastatic Gastric Cancer
  • Figure 15: Herceptin's Development in G/GEJAC
  • Figure 16: Development of Cyramza in G/GEJAC
  • Figure 17: Development of TS-1 in G/GEJAC
  • Figure 18: Development of Abraxane in Gastric Cancer
  • Figure 19: G/GEJAC - Phase III Pipeline, 2015
  • Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in G/GEJAC, 2014-2024
  • Figure 21: Kadcyla's Development in G/GEJAC
  • Figure 22: Clinical and Commercial Positioning of Kadcyla
  • Figure 23: Perjeta's Development in G/GEJAC
  • Figure 24: Clinical and Commercial Positioning of Perjeta
  • Figure 25: Keytruda's Development in G/GEJAC
  • Figure 26: Clinical and Commercial Positioning of Keytruda
  • Figure 27: Opdivo's Development in G/GEJAC
  • Figure 28: Clinical and Commercial Positioning of Opdivo
  • Figure 29: Napabucasin 's Development in G/GEJAC
  • Figure 30: Clinical and Commercial Positioning of Napabucasin
  • Figure 31: Lynparza's Development in G/GEJAC
  • Figure 32: Clinical and Commercial Positioning of Lynparza
  • Figure 33: Nimotuzumab's Development in Gastric Cancer
  • Figure 34: Clinical and Commercial Positioning of Nimotuzumab
  • Figure 35: TAS-118's Development in Gastric Cancer
  • Figure 36: Clinical and Commercial Positioning of TAS-118
  • Figure 37: GS-5745 's Development in G/GEJAC
  • Figure 38: Clinical and Commercial Positioning of GS-5745
  • Figure 39: Clinical and Commercial Positioning of masitinib
  • Figure 40: Global Sales of Branded Products for G/GEJAC by Company, 2014-2024
  • Figure 41: Company Portfolio Gap Analysis in G/GEJAC, 2014-2024
  • Figure 42: Bristol-Myers Squibb SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 43: Eli Lilly SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 44: Merck & Co. SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 45: Roche SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 46: Taiho SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 47: Sumitomo Dainippon SWOT Analysis in G/GEJAC, 2014-2024
  • Figure 48: Global Sales for G/GEJAC by Region, 2014-2024
  • Figure 49: Sales for G/GEJAC in the US by Drug Class, 2014-2024
  • Figure 50: Sales for G/GEJAC in the 5EU by Drug Class, 2014-2024
  • Figure 51: Sales for Gastric Cancer in Japan by Drug Class, 2014-2024
  • Figure 52: Sales for G/GEJAC in China by Drug Class, 2014-2024
Back to Top